Table 1 Patient characteristics and management according to the presence of RV injury during ICU stay
|  | No RV injury (n = 45) | RV injury (n = 73) | p-value |
|---|---|---|---|
Clinical characteristics | |||
 Age (years) | 64 (59–70) | 67 (61–74) | 0.20 |
 Gender (male), n (%) | 33 (73) | 51 (70) | 0.69 |
 SAPS-2 score | 38 (29–51) | 45 (34–67) | 0.05 |
 SOFA score on ICU admission | 6 (3–9) | 8 (4–11) | 0.12 |
 Body mass index (kg/m2) | 28 (26–30) | 28 (26–31) | 0.90 |
 Obesity, n (%) | 13 (29) | 27 (37) | 0.37 |
 Arterial hypertension, n (%) | 18 (40) | 40 (55) | 0.12 |
 Diabete mellitus, n (%) | 10 (22) | 25 (34) | 0.16 |
 Dyslipidemia, n (%) | 7 (16) | 24 (33) | 0.04 |
 Smokers, n (%) | 8 (18) | 9 (12) | 0.41 |
 Coronary artery disease, n (%) | 4 (9) | 7 (10) | 0.90 |
 Stroke, n (%) | 1 (2) | 5 (7) | 0.27 |
 Chronic heart failure, n (%) | 2 (4) | 2 (3) | 0.62 |
 Chronic respiratory disease, n (%) | 0 (0) | 5 (7) | 0.07 |
 Chronic kidney disease, n (%) | 5 (11) | 15 (21) | 0.18 |
 Immunosuppression, n (%) | 5 (11) | 19 (26) | 0.05 |
 Renin-Angiotensin System Blockers, n (%) | 15 (33) | 31 (43) | 0.32 |
 Delay from onset of symptoms to ICU admission (days) | 8 (7–11) | 9 (6–12) | 0.98 |
Oxygenation variables at the time of TTE examination on ICU admission | |||
 pH | 7.50 (7.40- 7.50) | 7.40 (7.40–7.50) | 0.14 |
 FiO2 (%) | 0.7 (0.5–0.9) | 0.6 (0.5–0.8) | 0.48 |
 PaO2/FiO2 | 121 (80–190) | 112 (79–165) | 0.50 |
 PaCO2 (mmHg) | 35 (32–40) | 39 (33–43) | 0.05 |
 Blood lactate level (mmol/L) | 1.0 (0.8–1.3) | 1.2 (1.0–1.5) | 0.03 |
Biological variables on ICU admission | |||
 Leukocytes (G/L) | 8.5 (7.0–11.0) | 8.4 (6.7–11.2) | 0.95 |
 Neutrophils (G/L) | 7.4 (6.1–9.9) | 7.3 (5.6–10.3) | 0.93 |
 Platelet count (G/L) | 228 (186–287) | 232 (180–292) | 1.00 |
 Lymphocytes (G/L) | 0.7 (0.5–0.9) | 0.7 (0.5–0.9) | 0.87 |
 Fibrinogen (g/L) | 5.7 (4.8–7.3) | 6.4 (5.4–7.7) | 0.14 |
 D-Dimers (µg/L) | 1099 (679–2255) | 1206 (709–2256) | 0.69 |
 Protein C reactive (mg/L) | 122 (71–268) | 136 (91–207) | 0.93 |
 Procalcitonin (ng/L) | 0.30 (0.20–0.80) | 0.30 (0.10–0.80) | 0.80 |
 Ferritin (ng/mL) | 1066 (575–1949) | 1096 (781–2751) | 0.38 |
 Interleukin-6 (pg/mL) | 70 (17–168) | 64 (26–184) | 0.76 |
 Plasma creatinine (µmol/L) | 73 (57–104) | 73 (61–104) | 0.86 |
 Troponin (ng/L) | 21 (16–46) | 17 (16–35) | 0.16 |
 N-terminal pro B-type natriuretic peptide (pg/mL) | 116 (52–214) | 206 (69–893) | 0.04 |
Management during ICU stay | |||
 High-flow nasal oxygen therapy, n (%) | 29 (64) | 32 (44) | 0.03 |
 Non invasive ventilation, n (%) | 1 (2) | 3 (4) | 0.58 |
 Intubation, n (%) | 27 (60) | 58 (80) | 0.02 |
 Corticosteroids, n (%) | 36 (80) | 59 (81) | 0.91 |
 Antiviral drugs, n (%) | 6 (13) | 9 (12) | 0.87 |
 Tocilizumab, n (%) | 19 (42) | 18 (25) | 0.05 |
 Hydroxychloroquine, n (%) | 3 (7) | 5 (7) | 0.97 |
 Low-dose thrombophylaxis, n (%) | 2 (4) | 8 (11) | 0.22 |
 Enhanced intermediate-dose thrombophylaxis, n (%) | 36 (80) | 52 (71) | 0.29 |
 Curative anticoagulation, n (%) | 7 (16) | 18 (25) | 0.24 |
 Norepinephrine, n (%) | 18 (40) | 50 (69) |  < 0.01 |
 Dobutamine, n (%) | 0 (0) | 1 (1) | 0.43 |
 Neuromuscular blocker agents, n (%) | 21 (47) | 51 (70) | 0.01 |
 Prone positioning, n (%) | 30 (67) | 57 (78) | 0.17 |
 Nitric oxide, n (%) | 26 (58) | 27 (37) | 0.03 |
 Venovenous ECMO, n (%) | 1 (2) | 3 (4) | 0.58 |
 Renal replacement therapy, n (%) | 8 (18) | 16 (22) | 0.59 |